Novo Nordisk, the maker of Wegovy, is taking legal action against a rival company over the production and sale of 'knock-off' weight-loss drugs. The lawsuit highlights concerns about the safety and efficacy of these compounded medications, which are not approved by regulatory bodies. Kerry Fulford, a pharmaceutical analyst, explains that compounding is a legal process allowing US drug makers to offer alternatives to patients with specific needs, but it's a gray area when it comes to quality control. Hims & Hers weight-loss drugs fall into this category, while Novo Nordisk's are not. The US Food and Drug Administration (FDA) has also taken steps to restrict the compounding of weight-loss drugs, citing the potential risks to consumers. Novo Nordisk's lawsuit warns that Hims & Hers' compounded drugs may contain dangerous impurities or incorrect dosages, leading to severe immune responses. This legal move comes as the Danish pharmaceutical company faces challenges, including job cuts and patent expirations, and it's not the first time they've faced scrutiny from the FDA, which has previously criticized their advertising practices for making exaggerated claims about the benefits of their products.
